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Abstract 
We studied a community cohort of 193 individuals exposed to endemic Schistosoma japonicum infection in 
the Dongting Lake region of China to assess subclinical morbidity and the 2-year benefit of curative therapy 
(praziquantel) administered in 1996. Prevalence and intensity of S. juponicum infection before treatment 
were 28% and 192 eggs per gram faeces (epg), respectively. Two years after cure, 22% of the cohort were re- 
infected, but with a lighter intensity (67 epg). Sixty-four subjects (37%) showed significant improvement in 
ultrasound parenchyma images after treatment and 5 1 subjects (54%) showed significant improvement of 
periportal fibrosis, Left-lobe enlargement also reversed (P < 0.05) and splenomegaly reversed in 6 of 8 cases 
and developed in only I. Two years post-treatment a dilated portal vein became less frequent, but the decline 
was not significant (16% vs 1 1 %, P > 0.05). The serum levels of laminin and collagen IV associated with re- 
infection and intensity and hyaluronic acid levels correlated with ultrasound findings (P < 0.01). Overall, 
treatment induced a marked decrease in subclinical hepatosplenic morbidity attributable to S. japonicum 
although low-intensity re-infection after treatment remained relatively frequent. Stratified analysis and 
logistic models evaluated potential confounding factors for assessment of treatment effects on hepatic 
fibrosis. S. juponicum infection and moderate-heavy alcohol intake interacted: improvement in parench- 
ymal morbidity was impeded among drinkers (P < 0.05). Chemotherapy focused on at-risk residents 
controls prevalent subclinical hepatic fibrosis but re-infection indicates the need for complementary control 
strategies. 
Keywords: Schistosoma japonicum, schistosomiasis, morbidity, re-infection, ultrasonography, fibrosis markers, China 
Introduction 
Schistosoma juponicum causes the most severe pathol- 
ogy of the 3 major schistosome species infecting humans 
(CHEN & MOTT. 1988: TORDAN et al.. 1993). The 
morbidity prevented by effective control has been stud- 
ied clinically, but subclinical forms detectable by ultra- 
sound are poorly understood and remain widespread in 
many endemic areas, even when infection prevalence is 
low (CAI et al.. 1992: MOTT et al.. 1992). Several million 
peoble are infected kith S. japonicum in China and the 
Philippines, and millions more are at risk. The disease 
has an adverse impact on rural economies and has been 
the focus of Chinese health programmes for decades (LI 
et al., 1993; SLEIGH et al., 1998a). Control in some parts 
of China has made great progress, even before the advent 
of praziquantel, using integrated ecological approaches 
sustained over 40 years (SLEIGH et al., 1998b). 
Schistosomiasis japonica remains a problem in marsh- 
land and mountain endemic areas of 6 Provinces in 
China (ANONYMOUS, 1997, CHEN & FENG, 1999). 
Reduction in morbidity is sought by use of periodic 
chemotherapy because many reports show its positive 
overall impact on schistosome prevalence, intensity and 
clinical disease (SLEIGH & MOTT, 1986; SLEIGH et&., 
1986; STURROCK et al., 1987; WIEST et al., 1992; 
BOOTH et al., 1996; OLDS et aZ., 1996; OLVEDA et al., 
1996; LI, Y. S. et al., 1997). But the impact of commu- 
nity-based praziquantel on subclinical S. japonicum 
morbidity in China is not yet known (CAI et al., 1992; 
ROSS et cd., 1998a). 
Hepatic fibrosis is the major morbid outcome of 
chronic infection with S. japonicum and many lesions 
are similar to those caused by S. mansoni. The liver 
pathology is caused by trapped eggs (SLEIGH & MOTT, 
1986; JORDAN et al., 1993) and is probably genetically 
associated (DESSEIN et al., 1999). Besides periportal 
fibrosis, there are changes in the liver parenchyma which 
are characteristic of S. juponicum infection. On ultra- 
sound and computerized tomography these appear as 
images thought to result from progressive septal fibrosis 
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and related clusters of calcified eggs (CHEUNG et al., 
1996). However, little is known of the natural history of 
periportal or septal fibrosis due to this parasite, or the 
hepatic effects of treatment, re-infection, or concurrent 
damage due to alcohol or hepatitis B virus infection. 
Ultrasonography can stage hepatic fibrosis induced by 
Schistosoma infection. Decreases in the thickness of 
portal vein walls and in echogenic bands have been 
detected after praziquantel therapy (HOMEIDA et al., 
1988; DOEHRING-SCHWERDTFEGER et al., 1989: OH- 
MAE et al., 1992; WIEST et al., 1993; CAI>~ al., i997; 
GERSPACHER-LARA et aI, 1997; BOISIER et al., 1998). 
Assay of serum levels of fibrosis markers may be a useful 
supplementary tool for monitoring changes in liver 
fibrosis (SHAHIN et aZ., 1992; KARDORFF et al., 1997; 
OBERTI et al., 1997; ESTERRE et al., 1998; RICARD- 
BLUM et al., 1999). 
We assessed the benefit of curing endemic S. japoni- 
cum infection by evaluating the effect on subclinical 
morbidity. The data were longitudinal and included 
repeated parasitological stool examinations, blinded 
sequential ultrasound findings and serum assay of 3 
markers for fibrosis in a community cohort. We docu- 
ment residual subclinical morbidity and changes that 
occurred after chemotherapeutic cure and re-infection 
over 2 years. We relate subclinical changes to new and 
past infection, alcohol intake, hepatitis B, and age. 
Materials and Methods 
Study area 
The 5 study villages (population 2990) are on 2 islands 
(Qingshan and Niangashan) in Dongting Lake, Hunan 
Province, China (LI, Y. S. et al., 1997; ROSS et al., 
1998a). Local residents, fishermen and buffaloes are the 
main infection source. Control programmes from 1988 
to 1996 included periodic praziquantel treatment for 
those infected, health education -and improved water 
sunnlies. Onlv 10% of the subiects in our cohort had 
never been treated before this study. Infection persists 
because of occupational exposure but clinically detect- 
able liver and spleen enlargement has been controlled 
(BOOTH etal., 1996;ROSS et&, 1998a). 
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Study design 
In 1996, we screened the resident population of the 
study area for active schistosome infection (1 stool, 
3 X 41.7-mg Kato-Katz smears) and for continuing 
water exposure or past infection (questionnaire). All 
250 individuals who were currently exposed and had 
past or present infection (ROSS et d., 1998a; LI et al., 
1999) received ultrasound assessment and then, whether 
found infected (n = 75) or not (n = 175) at baseline 
stool examination, received a single dose of praziquantel 
(40 mg/kg). Stool examination was repeated 7-8 weeks 
post-treatment and those still stool-positive (n = 13) 
were retreated, re-examined once more, and shown to 
be egg-negative. Thus all egg-positive subjects were 
cured in 1996 at the start of the study. In 1998, 2 years 
after treatment, 193 (77%) of the 250 subjects initially 
selected had a final parasitological (2 stools, 6 Kato- 
Katz smears per person) and ultrasound assessment. 
This group of 193 persons with ongoing exposure to 
re-infection constituted a 2-year prospective cohort 
enabling us to measure the influence of past, initial and 
re-infection with S. juponicum on the post-treatment 
evolution and regression of hepatic fibrosis. 
The 193 cohort subjects were similar to the 250 
eligible at baseline for mean age (39.7 vs 39.2 years), 
sex (males: 78% vs 76%), and initial schistosome infec- 
tion (prevalence: 30% vs 28%; intensity: 204 vs 
192 epg). Measurement bias for infection assessment 
was minimized by employing 2 experienced staff of the 
Hunan Institute of Parasitic Diseases to prepare and read 
all faecal smears. They were blinded to all other results. A 
10% random sample of all smears was read by a third 
senior microscopist: concordance exceeded 95%. To 
assess the influence of potential confounders of treat- 
ment effects, we recorded age, sex, reported alcohol 
intake and past history of anti-schistosomal chemo- 
therapy. To explore the biological correlates of findings 
we tested 97% of the 193 cohort members for serum 
fibrosis markers. For 105 of the 193 (random selection 
from the serum panel) we measured 5 hepatitis B 
markers. 
Ultrasound measurements 
Ultrasound measurements were conducted by the 
same experienced observer before and 2 years after 
treatment. This person directed abdominal ultrasound 
services at a large hospital and was blinded to all other 
results and to the underlying study purpose. The equip- 
ment used was a portable ultrasonograph (Sonolayer- 
LTM SAG33B; Toshiba, Tokyo, Japan) with a 3.5-MHz 
sector probe. Standard positions, views, measurements 
and classifications were according to the CAIRO proto- 
col (JENKINS & HATZ, 1992; CAI et aZ., 1997). 
Serum markers for fibrosis and hepatitis B 
Blood (5 mL) was taken at a final assessment in 1998. 
All sera were separated within 12 h, stored at -20°C, 
transported on dry ice to the Brisbane laboratory, and 
aliquoted and stored at -70°C until used. Three serolo- 
gical fibrosis markers were measured using enzyme- 
linked immunosorbent assays (EIA) for human laminin 
(LA) and collagen tvne IV (Fuji Chemical Industries, 
Tokyo, Japan) aid human hyaluronic acid (HA) (Chugai 
Diagnostics Science, Tokyo, Japan). Values exceeding 
reference means by >2 SD were considered abnormal; 
serum levels for LA, HA and collagen IV of 200 ng/mL, 
80 ng/mL and 150 ng/mL, respectively, were the upper 
limits of normal when tested among healthy persons. For 
assessing hepatitis B virus (HBV) exposure, 5 markers 
(HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc) 
were tested by EIA using commercial kits (Nanyan 
Institute of Biochemical Reagents, Shenzhen, China). 
Subjects positive for 1 of the 5 markers were considered 
positive for HBV exposure (LI, Y. et al., 1997). 
Statistical analysis 
Infection intensity (eggs per gram faeces; epg) among 
infected sub-groups was expressed as the geometric 
mean ( & geometric SD); for whole populations (includ- 
ing uninfected persons) the (egg count + 1) transforma- 
tion was used for individual counts before calculating 
geometric means. Relative frequencies were compared 
by x2 test for independent comparisons, or McNemar’s 
test for paired analyses. Student’s t-test (paired test when 
appropriate), or analysis ofvariance, was used to evaluate 
differences between or among group means. Non-para- 
metric analysis of variance (Kruskal-Wallis) was used if 
Bartlett’s test showed variances for compared groups 
were heterogeneous. Stratified analysis was used to 
assess potential confounding. For all outcomes assessed, 
the final logistic regression models included cure-of- 
heavy-infection (endpoint < 100 epg), moderate alcohol 
intake (weekly or more), older age (>35 years) and past 
recurrent infection (treatment >twice) as explanatory 
variables. These variables provided the best fit for the 
outcomes studied. This produced adjusted odds ratio 
estimates for each variable allowing for the influence of 
all other variables in the model. For statistical inference P 
values were set at < 0.05, and relative risk (RR) and odds 
ratio (OR) estimates were reported with 95% confidence 
intervals (CI). We distinguish between the magnitude of 
an effect (ranging from trivial to substantial) and its 
statistical significance (assessed by P-values) (ROTH- 
MAN, 1986). Analysis used EpiInfo and SPSS software. 
Ethical consideration 
This study was approved by the local body for medical 
ethics in Hunan Province, China, and by the University 
of Queensland and the Queensland Institute of Medical 
Research. Individuals found to be re-infected with S. 
juponicum after 2 years received prompt oral treatment 
with praziquantel. 
Results 
S. japonicum infection 
The initial prevalence of S. juponicum infection in the 
193 pre-treatment cohort subjects and intensity among 
those positive were 28% (54/193) and 192 f 3.5 epg, 
respectively. Heavy-intensity (epg 2400) individuals 
comprised 6.7% (n = 13) ofthe cohort; males had higher 
prevalence (29.8%) and intensity among positives 
(212 * 3.5 epg) than females (21.4%; 116 + 3.1 epg). 
Children and adolescents (aged <20 years, n = 16) had 
high prevalence and heavy intensity of infection (62.5%; 
3 16 epg) and infection then declined slowly with age 
(Fig.). Two years after cure, 22.3% (43/193) were found 
to be infected again with mean intensity among those 
positive (67 & 4.8 epg) one-third the corresponding level 
at baseline. Males had re-infection more commonly 
(25.8%, 39/151) and higher intensity among those posi- 
tive (77 + 4.8 epg) than females (9*5%, 4142; 
18 It 2.5 epg). 
Children and adolescents had the highest re-infection 
(37.5%) and incident intensity among those positive 
(130 f 10 epg). Only 2.6% (n = 5) of the cohort had re- 
infection intensity 3400 epg at endpoint. The age 
pattern of re-infection after treatment was similar to that 
before (Fig.). Sixteen subiects (29.6%. 16154) who were 
infected a;baseline became re-infected and 27 (19.4%, 
271139) who had been negative at baseline had new 
incident infections. For the 16 individuals positive before 
and 2 years after treatment, mean intensity (160 i 
5.6 epg) at endpoint was much lighter (P < 0.005, 
paired t-test) than at baseline (389 + 3.9 epg). 
Hepatic parenchymal abnormalities 
Compared to 1996, 36.8% (64/174) of subjects im- 
proved parenchymal fibrosis in 1998 and 13.5% (231 
17 1) became worse (Table 1). The prevalence of grade 
II-III in 1996 was 40.9% (n = 79) but fell significantly 
to 28.5% (n = 55) by 1998 (P<O.Ol). The prevalence 
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Figure. Cohort prevalence and intensity of infection with S. japonicum by age before (1996) and two years (1998) after praziquantel 
cure. 
Table 1. Dynamics of parenchyma grading before and 2 years after treat- 
ment for control of schistosomiasis japonica in a cohort of 193 subjects 




Parenchyma grading 1998 
Progressed Reversed 
0 I II III Total (%I (%I 
6 12 1 0 19 68.4 - 
16 71 8 0 95 8.4 16.8 
::I 0 1 31 23 15 ii 57 22 3.5 - 72.7 56.1 
Total (N) 23 115 47 8 193 (n = 23) (n = 64) 
of grade II-III rose steadily as age increased (Table 2). 
Alcohol intake substantially and significantly impeded 
post-treatment improvement in grade II-III: 45.6% of 
heavy drinkers (2 weekly) improved in contrast to 70.8% 
of others (P < 0.05). Re-infection impeded improve- 
ment of grade II-III although this effect was less than for 
alcohol and was not significant: 51.2% (22/43) of re- 
infected improved and 64.7% (97/150) of others 
(P > 0.05). 
For reversal of grade II-III, adjusted ORs showed a 
substantial but not statistically significant positive cure- 
of-heavy-infection effect (OR = 2.55; 95% CI = 0.67- 
9.58). Reversal effects were substantial and significantly 
negative for alcohol (0.29; O.OS-0.91), older age (0.15; 
0.03-0.74) and past recurrent infection (0.32; O.lO- 
0.99). For incidence of grade II-III, the adjusted 
estimates were not statistically significant but the cure- 
of-infection effect appeared to be preventive (0.50; 
0.05-4.99) and alcohol promotive (1.75; 0.35-8.87); 
age and past recurrent infection had almost no effect. 
Periponal thickness 
Periportal thickening was found in 48.7% (n = 94) in 
1996and39.4% (n = 76) in 1998 (P<O.O5): overthe 
years 54.3% (51194) improved and 10% (19/190) got 
worse (Table 3). No one with grade II deteriorated, but 1 
of 3 cases with grade III improved. Alcohol, re-infection, 
past infection, age and HBV had little influence on 
reversal of grade II-III. For incidence of grade II-III 
significant associations with explanatory variables were 
not found; however, OR point estimates for cure-of- 
heavy-infection (OR = 0.49; 95% CI = 0.044.98) sug- 
gested it may be preventive whereas older age (1.81; 
Table 2. Periportalandparenchyma (gradingII-III) changes in 193 subjects 
by age at baseline and 2 years post treatment for control of schistosomiasis 
japonica 
Periportal 
(% of II-III) 
Parenchyma 
(% of II-III) 
(years) n 1996 1998 1996 1998 
<20 16 6.3 0 6.3 6.3 
20-35 iii 2z.96 3.4 22.4 12.1 
36-49 12.3 50.8 30.8 
50+ 54 33.3 20.4 59.3 50.0 
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Table 3. Dynamics of periportal thickening measured by ultrasound in 193 
cohort subjects from the schistosomiasis japonica-endemic Dongting Lake 




Periportal grading 1998 
Progressed Reversed 
0 I II III Total (%) (%I 
; 86 24 25 11 2 6 i 99 13.1 12.7 43-6 
::I 7 0 19 0 10 1 0 2 5: 3 0 - 72.2 113 
Total (N) 117 55 19 2 193 (n = 19) (n = 51) 
0.33-9.83) and past recurrent infection (7.26; 0.80- 
65.4 1) appeared to be promotive. 
Portal vein size 
A dilated portal vein (DPV) was demonstrated in 
16.1% (n = 31) and 11.4% (n = 22) in 1996 and 
1998, respectively (P > 0.05). Subjects not re-infected 
had 8% (12/150) prevalence of DPV in 1998, substan- 
tially and significantly less than the prevalence of 23.3% 
(1 O/43) among those re-infected (P < 0.01). Adjusted 
ORs for 2-year incidence of DPV showed a substantial 
and significant preventive effect for cure-of-heavy-infec- 
tion (OR = 0.17; 95% CI = 0.03-0.83), and moderate 
but not significant promotive effects for alcohol (1.43; 
0.40-513), age (1.55; 0.43-5.62) and past recurrent 
infection (155; 0.43-5.52). 
Left-lobe and spleen enlargement 
Left-lobe enlargement (LLE) was seen in 26.4% 
(n = 51) in 1996 and 19.2% (n= 37) in 1998 
(P< 0.05). Although 15.5% (22/142) of individuals 
without LLE in 1996 developed it by 1998, 68.6% (351 
5 1) of baseline LLE reversed (P < 0.05). Incident LLEl 
among the re-infected (25%) was higher than for those 
not re-infected (12.7%)(P > 0.05). A substantial (but 
not significant) apparent preventive effect was noted for 
cure-of-heavy-infection (OR = 0.22; 95% CI = 0.06- 
0.83). 
Splenomegaly occurred in only 4.1% (n = 8) in 1996 
and 1.6% (n = 3) in 1998. No one aged <26 years had 
splenomegaly. Six of the 8 1996 splenomegaly cases 
reverted after treatment. The 2 patients with persistent 
splenomegaly were aged >6 1 years. Only 1 person (aged 
55 years) developed splenomegaly after treatment. 
Correlation of serum fibrosis markers with infection and 
morbidity 
Abnormal levels of LA, HA and collagen IV were 
found for 27.7%, 31.9% and 25.5% of the cohort, 
respectively. LA and collagen IV were higher in males; 
LA and collagen IV, but not HA, correlated with re- 
infection (Table 4). Subjects with moderate or heavy 
intensity infections (> 100 epg) had higher mean levels 
(320 * 200 ng/mL) of IA than those with light intensity 
(211 f 7 1 ng/mL) or no re-infection (182 f 97 ng/mL) 
(P < 0.01). Five cases with heavy intensity re-infection 
(epg >400) had even higher collagen levels 
(307 * 387 ng/mL), double the level for those not re- 
infected (153 f 175 ng/mL) (P < 0.05). LA and col- 
lagen did not correlate with parenchymal and periportal 
findings (P > 0.05). HA correlated with parenchyma 
stages (P < 0.001) (Table 5). Older subjects (aged >50 
years) had higher HA levels (157 f 163 ng/mL) than 
those younger (aged <50 years; 58 f 75 ng/mL; 
P < 0.01). 
Table 4. Serum levels of three fibrosis markers in 188 subjects with or 
without re-infection with S. japonicum 
Infection Laminin 
status n bg/mL) 
Not re-infected 145 182f97 
Re-infected 43 243 zt 127 
P value” <O~OO 1 
Values in the first 2 rows are mean f SD. 
“Kruskal-Wallis test. 
Collagen IV Hyaluronic acid 
(ng/mL) bg/mU 
153 f 175 83 It 109 
197 f 226 98 f 134 
<0*05 0 > 0.05 
Table 5. Serum levels of three fibrosis markers and endpoint ultrasound staging in 188 subjects in 1998, two 
years after their treatment for schistosomiasis japonica 
Parenchyma grading Periportal grading 
Fibrosis 
markers (n ,021) (n =‘112) (n f47) 
III II-III 
(n = 8) Pvalue” (n =‘115) (n 252) (n = 21) Pvalue” 
Laminin 185flOl 193f94 203&142 219f85 0.6 190 f 112 209 I!= 106 195 + 77 0.45 
Hyaluronic 76+117 67f74 111*129 242zt280 0.001 82 f 112 79 + 74 130 zt 148 0.09 
-acid 
Collagen IV 170 & 222 151 f 182 178 it 181 217 & 222 0.12 155 zt 175 178 f 221 168 -f 171 0.76 
Values are mean i SD (ng/mL) 
aKruskal-Wallis test. 
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Cumulative incidence and correlations for HBV infection 
Exposure to HBV affected 39% of the cohort in 1998. 
Positive results for HBsAg, anti-HBs, HBeAg, anti-HBe 
and anti-HBc were found in 19%, 6*7%, 5.7%, 25.7% 
and 18.1%, respectively. HBV prevalence did not vary 
much (P > 0.05) by age, sex, re-infection or ultrasono- 
graphy findings. The serum levels of fibrosis markers in 
the 6 HBeAg-positive cases were higher (LA 
435 & 300 ng/mL; HA 165 + 89 ng/mL; collagen IV 
438 & 459 ng/mL) than those (n = 99) HBeAg-nega- 
tive (LA 194 If 9 1 ng/mL; HA 91 f 134 ng/mL; col- 
lagen IV 153 f 167<g/mL). These differ&es -were 
statisticallv significant (Kruskal-Wallis test. P < 0.051 
for LA ani Hz. When this comparison was restricted to 
those positive for HBV, the HBeAg-negative group still 
had lower levels of all 3 markers than those who were 
HBeAg-positive. However, the differences were signifi- 
cant for only LA and HA (Kruskal-Wallis test, 
P < 0.05). 
Discussion 
Praziquantel was first manufactured in China in 1984 
and has been used for community treatment in the study 
locality since 1988. Effectiveness of praziquantel is still 
unquestioned in this area and we observed an 83% cure 
(62/75) after a single dose. Most infected individuals in 
our study area now have low worm burdens (and 
infrequent splenomegaly) because chemotherapy has 
been used for more than a decade and other methods 
of control have been used since 1956. 
We measured the impact of curative treatment on S. 
japonicum infection and subclinical morbidity. After 2 
years the infection incidence was hi& (22%) but the 
prevalence and geometric mean inten& df infeition fell, 
respectively, 21% and 65% below pre-treatment levels. 
Baseline subclinical hepatic morbidity was highly pre- 
valent but fell by one-third or more over the 2 years after 
curative treatment. In this area a 2-year treatment cycle 
with coverage focused on those at risk will not control 
transmission but will control disease. 
Parenchymal abnormalities were the most common 
and distinctive findings for all subclinical morbidity due 
to S. japonicum infection. This is notable given that these 
ultrasound features are found only with S. japonicum 
infection. Parenchymal pathology was slow to develop 
and was much less evident among the young, even when 
they were heavily infected. Despite the slow develop- 
ment, 30% of stage II-III cases improved quickly over 
the 2 years after treatment. But moderate alcohol intake, 
age >35 years and past recurrent infection impeded 
treatment-related reversal of parenchymal abnormalities 
substantially and significantly. In contrast, periportal 
fibrosis was less prevalent, slower to reverse and had no 
clear relationship to alcohol. Past recurrent infection was 
strongly related to periportal fibrosis, and prevention of 
heavy infection slowed its incidence substantially. Portal 
vein dilation fell substantially and significantly over the 2 
years; its incidence was significantly related to re-infec- 
tion. Several other findings, although not statistically 
significant, were noteworthy and consistent with our 
knowledge of the underlying biology. Thus left-lobe 
enlargement was associated with re-infection, and its 
reversal with cure of heavy infection. Spleen enlargement 
reduced substantially and persisted or developed only in 
3 subjects, all aged >50 years. 
With S. japonicum, few reports have explored the 
dynamic relationship over time between infection and 
hepatic fibrosis measured by ultrasound using the 
CAIRO standard. Previous studies have correlated peri- 
portal fibrosis measured by ultrasound with biopsy- 
proven liver pathology in individuals infected by S. 
mansoni (HOMEIDA et al., 1988; DOEHRING- 
SCHWERDTFEGER er aZ., 1989). In this study we could 
not perform liver biopsies. The area is remote and lacks 
hospital facilities or adequate transport. In such a setting, 
risks of liver biopsy outweigh personal benefit and per- 
formance of the procedure would be unethical. 
Liver fibrosis is a complex process involving produc- 
tion and deposition of insoluble components that con- 
stitute the extracellular matrix. The major components 
of basement membranes are type IV collagen, LA and 
heparin sulphate proteoglycan. HA is a glycosaminogly- 
can and is mainly synthesized by hepatic stellate cells and 
taken up and degraded almost exclusively in hepatic 
sinusoidal endothelial cells. In this study we found serum 
concentrations of LA and collagen IV correlated well 
with active schistosome infection, manifest by egg excre- 
tion. This suggests that LA and collagen IV may be 
involved in inflammatory granulomas and pseudotuber- 
cle formation around trapped eggs. Serum concentration 
of HA, but not of LA and collagen IV, correlated well 
with ultrasound grading of fibrosis. Thus it appears that 
LA and collagen IV levels respond to egg-associated 
inflammation and HA to fibrosis. Serum markers for 
individuals were rather insensitive and non-specific 
predictors of fibrosis but mean levels of these markers 
in populations may indicate endemic infection and 
fibrosis that would fall with effective control. 
Prevalence of HBV exposure was similar for patients 
with and without hepatic fibrosis detected by ultrasound. 
HBV was studied in only 54% of the cohort and our data 
lackedstatisticalpowerforinvestigatingthisfactorasaco- 
determinant offibrosis. But the stable HBVexposure rate 
(40% in 1992 (LI, Y. et al., 1997) and 39% in 1998) 
suggests that improvement in hepatosplenic morbidity in 
the 2 years that followed praziquantel treatment in 1996 
cannotbeattributedtochangesinHBVinthispopulation. 
Age or body height may influence the normal size of 
organs measured by ultrasound (YAZDANPANAH et al., 
1997). We did not adjust for body weight and height 
because our study involved self-comparison of ultraso- 
nography before and after treatment. Also, we did not use 
the CAIRO integrated grading system for hepatic fibrosis 
as we aimed to assess the dynamics separately for both 
parenchyma and periportal changes. Alcohol exposure 
was investigated by questionnaire and we accept that 
consumption of alcohol based on self-report is difficult to 
validate. Despite the measurement difficulties, trends 
linking alcohol to parenchymal features of S. japonicum 
infection were easily detected, and have not been re- 
ported before. 
Our 2-year study quantified the substantial morbidity 
benefit oflowering S. japonicum worm burdens by at least 
half for 2 years. Although re-infection 2 years after 
therapy remained relatively frequent, both the intensity 
of infection and the morbidity attributable to this parasite 
were markedly reduced. But chemotherapy-based con- 
trol in China faces several problems, including low 
compliance from local populations (WEST et al., 1991; 
LI, Y. S. etal., 1997; ROSS etal., 1998b) partlycausedby 
concurrent over-prescribing of supplementary medi- 
cines as an income-earning device for village doctors. 
As well, because successive stool egg counts vary and 
symptoms may be minimal, lightly infected persons may 
remain undetected and miss periodic community-based 
treatments. 
In future, control based on chemotherapy in China 
could focus on those shown by questioniaire or past 
history to be at high risk of infection. Also. our data show 
that moderate-heavy alcohol intake exacerbates schisto- 
some-induced parenchymal morbidity, and this message 
should be incorporated into health education and 
healthy lifestyle programmes of the future. In addition, 
ecological interventions to reduce human or bovine 
exposure or faecal contamination of transmission sites, 
or vaccines that prevent infection or lower egg produc- 
tion would complement the power of praziquantel. 
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